Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-08-29

FDA Approved: OLMESARTAN MEDOXOMIL — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)

View source ↗

Summary

FDA approved a supplemental application for olmesartan medoxomil submitted by Glenmark Pharmaceuticals Inc., USA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • OLMESARTAN MEDOXOMIL (olmesartan medoxomil)

Snippet

SUPPL AP for OLMESARTAN MEDOXOMIL (OLMESARTAN MEDOXOMIL)